Fangxin Hong

15.7k citations

132 papers · 9.6k indexed · 4 hit papers · h-index 35

Molecular Biology top 2%
Plant Science top 0.5%
Oncology top 2%
Pathology and Forensic Medicine top 0.5%
Geophysics top 5%

Co-authors: Joanne Chory Jason Lim Todd C. Mockler Jennifer L. Nemhauser Marci Surpin Shai Koussevitzky Gilberto Sachetto‐Martins Ron Mittler
Topics: Lymphoma Diagnosis and Treatment (54 papers)Lung Cancer Treatments and Mutations (21 papers)Cancer survivorship and care (17 papers)
Cited by: Plant Science Pathology and Forensic Medicine Oncology
Journals: Nature Science Cell
Partner nations: United States Canada United Kingdom

In The Last Decade

Fangxin Hong

128 papers receiving 9.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Signals from chloroplasts converge to regulate nuclear gene expression.

2007 3.0k citations Todd C. Mockler, Fangxin Hong et al. profile →
Rapid Synthesis of Auxin via a New Tryptophan-Dependent Pathway Is Required for Shade Avoidance in Plants

2008 828 citations Fangxin Hong, Joanne Chory et al. profile →
Different Plant Hormones Regulate Similar Processes through Largely Nonoverlapping Transcriptional Responses

2006 718 citations Fangxin Hong, Joanne Chory et al. profile →
RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis

2006 568 citations Fangxin Hong, Joanne Chory et al. profile →

Peers

Countries citing papers authored by Fangxin Hong

Since Specialization

Citations

This map shows the geographic impact of Fangxin Hong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fangxin Hong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fangxin Hong more than expected).

Fields of papers citing papers by Fangxin Hong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fangxin Hong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fangxin Hong. The network helps show where Fangxin Hong may publish in the future.

Co-authorship network of co-authors of Fangxin Hong

This figure shows the co-authorship network connecting the top 25 collaborators of Fangxin Hong. A scholar is included among the top collaborators of Fangxin Hong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fangxin Hong. Fangxin Hong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Utilizing Sweet Potato Genetic Diversity and Molecular Breeding Techniques for Resistance Breeding and Quality Improvement 2024 ·(unknown),Yuesheng Wang,Lingli Wang,Yongan Liu,Fangxin Hong,(unknown)	0
2	MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) 2024 ·Blood ·Matthew J. Pianko,Charlotte Pawlyn,Shang‐Yi Huang,Tadao Ishida,Douglas W. Sborov,Shinsuke Iida,Aravind Ramakrishnan,(unknown),Rakesh Popat,Steven R. Schuster,Junya Kuroda,Chia-Jen Liu,Anne Philippe,Umberto Conte,Fangxin Hong,Erik Vandendries,Rafaël Fonseca	0
3	Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers 2022 ·Nature ·Yoshihisa Kobayashi,(unknown),Jiaqi Li,Kristin S. Price,Lesli A. Kiedrowski,(unknown),Aaron Hardin,Zihan Wei,Fangxin Hong,Magda Bahcall,Prafulla C. Gokhale,Pasi A. Jänne	31
4	SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping 2021 ·JTO Clinical and Research Reports ·Marissa Lawrence,(unknown),Pablo Martínez,(unknown),(unknown),(unknown),Tristan Shaffer,Seyed Ali Hosseini,(unknown),Lee P. Lim,Fangxin Hong,(unknown),George R. Simon,Jonathan W. Riess,Mark M. Awad,Geoffrey R. Oxnard	2
5	Exploring the impact of a decision support algorithm to improve clinicians’ chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study 2021 ·BMC Cancer ·Robert Knoerl,Emanuele Mazzola,Fangxin Hong,(unknown),Nadine J. McCleary,Jennifer A. Ligibel,Kaitlen Reyes,Donna L. Berry	15
6	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408 2020 ·Clinical Cancer Research ·Andrew M. Evens,Fangxin Hong,Thomas M. Habermann,Ranjana H. Advani,Randy D. Gascoyne,Thomas E. Witzig,Andrew Quon,Erik A. Ranheim,Stephen M. Ansell,P. Cheema,(unknown),Timothy E. O’Brien,Jane N. Winter,Terrence P. Cescon,Julie Chang,Brad S. Kahl	16
7	Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status 2020 ·Journal for ImmunoTherapy of Cancer ·Joao V. Alessi,Biagio Ricciuti,(unknown),Fangxin Hong,Zihan Wei,Mizuki Nishino,Andrew J. Plodkowski,Peter Sawan,Jia Luo,Hira Rizvi,Brett W. Carter,John V. Heymach,Mehmet Altan,Matthew D. Hellmann,Mark M. Awad	40
8	Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial 2020 ·The Lancet Haematology ·Catherine Diefenbach,Fangxin Hong,Richard F. Ambinder,Jonathon B. Cohen,Michael J. Robertson,Kevin A. David,Ranjana H. Advani,Timothy S. Fenske,Stefan K. Barta,Neil Palmisiano,Jakub Svoboda,David Morgan,Reem Karmali,Elad Sharon,Howard Streicher,Brad S. Kahl,Stephen M. Ansell	97
9	Threats of Bots and Other Bad Actors to Data Quality Following Research Participant Recruitment Through Social Media: Cross-Sectional Questionnaire 2020 ·Journal of Medical Internet Research ·Rachel Pozzar,Marilyn J. Hammer,Meghan Underhill‐Blazey,Alexi A. Wright,James A. Tulsky,Fangxin Hong,Daniel A. Gundersen,Donna L. Berry	181
10	Relationship between individual and family characteristics and psychosocial factors in persons with familial pancreatic cancer 2018 ·Psycho-Oncology ·Meghan Underhill‐Blazey,Fangxin Hong,(unknown),Traci M. Blonquist,Sapna Syngal	10
11	Impact of Electronic Self-Assessment and Self-Care Technology on Adherence to Clinician Recommendations and Self-Management Activity for Cancer Treatment–Related Symptoms: Secondary Analysis of a Randomized Controlled Trial 2018 ·JMIR Cancer ·Robert Knoerl,Fangxin Hong,Traci M. Blonquist,Donna L. Berry	2
12	A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group 2017 ·Blood ·Andrew M. Evens,Fangxin Hong,Thomas M. Habermann,Ranjana H. Advani,Randy D. Gascoyne,Thomas E. Witzig,Andrew Quon,Erik A. Ranheim,P. Cheema,(unknown),Timothy E. O’Brien,Jane N. Winter,Terrence P. Cescon,Julie Chang,Brad S. Kahl	4
13	Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402 2014 ·Journal of Clinical Oncology ·Brad S. Kahl,Fangxin Hong,Michael E. Williams,Randy D. Gascoyne,Lynne I. Wagner,John C. Krauss,Thomas M. Habermann,Lode J. Swinnen,Stephen J. Schuster,Christopher G. Peterson,Mark D. Sborov,Sabrina Martín,Matthias Weiss,W. Christopher Ehmann,Sandra J. Horning	138
14	Patient cues and symptoms of psychosocial distress: what predicts assessment and treatment of distress by oncology clinicians? 2014 ·Psycho-Oncology ·Lisa Kennedy Sheldon,Traci M. Blonquist,(unknown),Fangxin Hong,Donna L. Berry	4
15	The electronic self report assessment and intervention for cancer: promoting patient verbal reporting of symptom and quality of life issues in a randomized controlled trial 2014 ·BMC Cancer ·Donna L. Berry,Fangxin Hong,Barbara Halpenny,A. H. Partridge,(unknown),Jesse R. Fann,Seth Wolpin,William B. Lober,Nigel Bush,Upendra Parvathaneni,Dagmar Amtmann,Rosemary Ford	52
16	Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499 2012 ·Journal of Clinical Oncology ·Mitchell R. Smith,Hailun Li,Leo I. Gordon,Randy D. Gascoyne,Elisabeth Paietta,Andres Forero‐Torres,Brad S. Kahl,Ranjana H. Advani,Fangxin Hong,Sandra J. Horning	55
17	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496) 2012 ·Journal of Clinical Oncology ·Leo I. Gordon,Fangxin Hong,Richard I. Fisher,Nancy L. Bartlett,Joseph M. Connors,Randy D. Gascoyne,Henry Wagner,Patrick J. Stiff,Bruce D. Cheson,Mary Gospodarowicz,Ranjana H. Advani,Brad S. Kahl,Jonathan W. Friedberg,Kristie A. Blum,Thomas M. Habermann,Joseph M. Tuscano,Richard T. Hoppe,Sandra J. Horning	194
18	Metabolic sugar signal promotes Arabidopsis meristematic proliferation via G2 2010 ·Developmental Biology ·(unknown),(unknown),Fangxin Hong,Joanne Chory,Xuelin Wu	62
19	Network Discovery Pipeline Elucidates Conserved Time-of-Day–Specific cis-Regulatory Modules 2008 ·PLoS Genetics ·Todd P. Michael,Todd C. Mockler,Ghislaı̀n Breton,(unknown),(unknown),(unknown),Samuel P. Hazen,Rongkun Shen,Henry D. Priest,Christopher M. Sullivan,Scott A. Givan,Marcelo J. Yanovsky,Fangxin Hong,Steve A. Kay,Joanne Chory	420
20	Functional Empirical Bayes Methods for Identifying Genes with Different Time-course Expression Profiles 2004 ·eScholarship (California Digital Library) ·Fangxin Hong,Hongzhe Li	1

About Fangxin Hong

Fangxin Hong is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics, having authored 132 papers that have together received 9.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (54 papers), Lung Cancer Treatments and Mutations (21 papers) and Cancer survivorship and care (17 papers). The work is most often cited by research in Plant Science (3.3k citations), Pathology and Forensic Medicine (1.4k citations) and Oncology (1.6k citations). Fangxin Hong has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Joanne Chory, Jason Lim, Todd C. Mockler, Jennifer L. Nemhauser, Marci Surpin, Shai Koussevitzky, Gilberto Sachetto‐Martins, Ron Mittler, Rainer Breitling and Donna L. Berry. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact